Crestwood Advisors Group LLC Sells 3,404 Shares of Zoetis Inc. (NYSE:ZTS)

Crestwood Advisors Group LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 215,371 shares of the company's stock after selling 3,404 shares during the period. Crestwood Advisors Group LLC's holdings in Zoetis were worth $35,461,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Brighton Jones LLC grew its holdings in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in Zoetis by 5.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock worth $68,354,000 after purchasing an additional 21,470 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in shares of Zoetis by 61.0% in the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock worth $497,000 after acquiring an additional 1,157 shares during the period. HUB Investment Partners LLC lifted its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares during the period. Finally, Millstone Evans Group LLC acquired a new stake in shares of Zoetis in the 4th quarter worth approximately $68,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS traded down $1.29 on Monday, hitting $147.31. 2,996,578 shares of the stock were exchanged, compared to its average volume of 2,624,290. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a market capitalization of $65.59 billion, a PE ratio of 24.68, a P/E/G ratio of 2.46 and a beta of 0.91. The business's fifty day moving average is $160.77 and its 200 day moving average is $161.42. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 earnings per share. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.36%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ZTS shares. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday. Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $204.63.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.